
Gastroenterologist

No OPD information available
Colitis
Viral Gastroenteritis
Crohn's Disease
Hemorrhagic Proctocolitis
Malnutrition
Ulcerative Colitis
Colostomy
Heart Tumor
Ileostomy
Iron Deficiency Anemia
Necrosis
Pericarditis
Vitamin D Deficiency
Simon Ghaly is a male healthcare provider who helps people with various digestive and heart problems. He can assist with conditions like colitis, viral gastroenteritis, Crohn's disease, and more. Some patients may need surgeries like colostomy or ileostomy, which Simon Ghaly is experienced in.
Patients trust Simon Ghaly because he listens to them carefully and explains things in a way they can understand. He is known for being kind and compassionate towards his patients, making them feel comfortable and supported during their treatment.
To stay updated with the latest medical knowledge, Simon Ghaly reads research articles and attends conferences. This helps him provide the best care for his patients and stay informed about new treatments and technologies.
Simon Ghaly works well with other medical professionals, collaborating to ensure patients receive comprehensive care. He values teamwork and respects his colleagues, creating a positive work environment that benefits everyone involved.
Simon Ghaly's work has positively impacted many patients' lives. For example, his research on dietary patterns and fiber intake in inflammatory bowel disease has helped improve disease management for many adults. Additionally, his involvement in clinical trials for medications like Mirikizumab shows his dedication to finding new and effective treatments for conditions like Crohn's disease.
In summary, Simon Ghaly is a dedicated healthcare provider who uses his expertise and compassion to help patients with digestive and heart issues. Through his commitment to ongoing learning, collaboration with colleagues, and impactful research, Simon Ghaly continues to make a difference in the lives of those he treats.
Enrollment Status: Active not recruiting
Published: January 24, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
